Characterization of low level viraemia in HIV-infected patients receiving boosted protease inhibitor-based antiretroviral regimens

To understand the pathogenesis of low level viraemia (LLV) in HIV-infected patients on boosted protease inhibitors (PI/b), we enrolled 34 subjects with a median HIV-RNA 79 copies/mL and followed them for 15 months. Samples for next generation sequencing were collected at three time-points. Two showe...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Francesca Ferretti, Nicola E. Mackie, Gurmit Kaur Jagjit Singh, Julie Fox, Steve Kaye, Myra O. McClure, Graham Taylor, Marta Boffito
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Taylor & Francis Group 2019-09-01
Serie:	HIV Research & Clinical Practice
Soggetti:	hiv resistance low level viremia gag protease inhibitors
Accesso online:	http://dx.doi.org/10.1080/25787489.2020.1716159
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!